Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901

Arkadiusz Z. Dudek; Xiaofei Wang; Lin Gu; Stephanie Duong; Thomas E. Stinchcombe; Robert Kratzke; Hossein Borghaei; Everett E. Vokes; Hedy L. Kindler

doi:10.1016/j.cllc.2020.06.025

Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901

Arkadiusz Z. Dudek, Xiaofei Wang, Lin Gu, Stephanie Duong, Thomas E. Stinchcombe, Robert Kratzke, Hossein Borghaei, Everett E. Vokes, Hedy L. Kindler

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

The role of maintenance therapy after first-line platinum and pemetrexed for malignant pleural mesothelioma is unknown. We performed the first-to-date randomized trial to determine if continuation of pemetrexed would improve progression-free survival over that of observation and found that primary endpoint was not different between study arms. Therefore, we cannot recommend pemetrexed continuation maintenance for treatment of malignant pleural mesothelioma.

Original language	English (US)
Pages (from-to)	553-561.e1
Journal	Clinical Lung Cancer
Volume	21
Issue number	6
DOIs	https://doi.org/10.1016/j.cllc.2020.06.025
State	Published - Nov 2020

Bibliographical note

Publisher Copyright:
© 2020 The Author(s)

Keywords

Continuation pemetrexed
Phase II study
Progression-free survival
Unresectable mesothelioma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.cllc.2020.06.025

OpenUrl availability

Full text

Cite this

@article{af6af54c29c9466093e72db9d6eebd1d,

title = "Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901",

abstract = "The role of maintenance therapy after first-line platinum and pemetrexed for malignant pleural mesothelioma is unknown. We performed the first-to-date randomized trial to determine if continuation of pemetrexed would improve progression-free survival over that of observation and found that primary endpoint was not different between study arms. Therefore, we cannot recommend pemetrexed continuation maintenance for treatment of malignant pleural mesothelioma.",

keywords = "Continuation pemetrexed, Phase II study, Progression-free survival, Unresectable mesothelioma",

author = "Dudek, {Arkadiusz Z.} and Xiaofei Wang and Lin Gu and Stephanie Duong and Stinchcombe, {Thomas E.} and Robert Kratzke and Hossein Borghaei and Vokes, {Everett E.} and Kindler, {Hedy L.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = nov,

doi = "10.1016/j.cllc.2020.06.025",

language = "English (US)",

volume = "21",

pages = "553--561.e1",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma

T2 - CALGB 30901

AU - Dudek, Arkadiusz Z.

AU - Wang, Xiaofei

AU - Gu, Lin

AU - Duong, Stephanie

AU - Stinchcombe, Thomas E.

AU - Kratzke, Robert

AU - Borghaei, Hossein

AU - Vokes, Everett E.

AU - Kindler, Hedy L.

PY - 2020/11

Y1 - 2020/11

N2 - The role of maintenance therapy after first-line platinum and pemetrexed for malignant pleural mesothelioma is unknown. We performed the first-to-date randomized trial to determine if continuation of pemetrexed would improve progression-free survival over that of observation and found that primary endpoint was not different between study arms. Therefore, we cannot recommend pemetrexed continuation maintenance for treatment of malignant pleural mesothelioma.

AB - The role of maintenance therapy after first-line platinum and pemetrexed for malignant pleural mesothelioma is unknown. We performed the first-to-date randomized trial to determine if continuation of pemetrexed would improve progression-free survival over that of observation and found that primary endpoint was not different between study arms. Therefore, we cannot recommend pemetrexed continuation maintenance for treatment of malignant pleural mesothelioma.

KW - Continuation pemetrexed

KW - Phase II study

KW - Progression-free survival

KW - Unresectable mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=85088790876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088790876&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2020.06.025

DO - 10.1016/j.cllc.2020.06.025

M3 - Article

C2 - 32727707

AN - SCOPUS:85088790876

SN - 1525-7304

VL - 21

SP - 553-561.e1

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 6

ER -

Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this